Skip to main content
Viewing from:
Department GEZ-LTA Erasmushogeschool
Intended for healthcare professionals
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Browse by collection
Archive
Authors
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Browse by collection
Archive
Authors
About
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
More
You are viewing from:
Department GEZ-LTA Erasmushogeschool
You are here
Home
Malignant Pleural Mesothelioma
Email alerts
Malignant Pleural Mesothelioma
JITC launches a new section: commentary and editorials
Christian M.
Capitini
,
Pedro
Romero
Journal for ImmunoTherapy of Cancer
Dec 2015,
3
(1)
28;
DOI:
10.1186/s40425-015-0073-1
FAP-specific re-directed T cells first in-man study in malignant pleural mesothelioma: experience of the first patient treated
Magdalena
Pircher
,
Petra
Schuberth
,
Pratiksha
Gulati
,
Simon
Sulser
,
Walter
Weder
,
Alessandra
Curioni
,
Christoph
Renner
,
Ulf
Petrausch
Journal for ImmunoTherapy of Cancer
Dec 2015,
3
(Suppl 2)
P120;
DOI:
10.1186/2051-1426-3-S2-P120
Anti-mesothelin vaccine CRS-207 with or without low-dose cyclophosphamide plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM)
Raffit
Hassan
,
Evan
Alley
,
Hedy
Kindler
,
Scott
Antonia
,
Thierry
Jahan
,
Anish
Thomas
,
Somayeh
Honarmand
,
Aimee L
Murphy
,
John J
Grous
,
Dirk G
Brockstedt
Journal for ImmunoTherapy of Cancer
Dec 2015,
3
(Suppl 2)
P161;
DOI:
10.1186/2051-1426-3-S2-P161
Immune responses following intrapleural administration of oncolytic SEPREHVIR in patients with malignant pleural mesothelioma
Kirsty
Learmonth
,
Lynne
Braidwood
,
Penella
Woll
,
Joe
Conner
Journal for ImmunoTherapy of Cancer
Dec 2015,
3
(Suppl 2)
P335;
DOI:
10.1186/2051-1426-3-S2-P335
Clinical experience with live-attenuated, double-deleted (LADD) listeria monocytogenes targeting mesothelin-expressing tumors
Dirk G
Brockstedt
,
Dung T
Le
,
Raffit
Hassan
,
Aimee
Murphy
,
John
Grous
,
Thomas W
Dubensky
,
Elizabeth M
Jaffee
Journal for ImmunoTherapy of Cancer
Nov 2013,
1
(Suppl 1)
P203;
DOI:
10.1186/2051-1426-1-S1-P203
Pre-clinical testing of malignant fibroblast activation protein-specific re-directed T cells for treatment of pleural mesothelioma
Petra C
Schuberth
,
Christian
Hagedorn
,
Shawn M
Jensen
,
Pratiksha
Gulati
,
Osiris Marroquin
Belaunzaran
,
Alex
Soltermann
,
Astrid
Jüngel
,
Christoph
Renner
,
Ulf
Petrausch
Journal for ImmunoTherapy of Cancer
Nov 2013,
1
(Suppl 1)
P35;
DOI:
10.1186/2051-1426-1-S1-P35
Special collections
COVID-19
(46)
Editor's choice
JITC
Aging and diversity, equity, and inclusion (DEI) with regard to cancer immunotherapy and understudied populations
Aging and diversity, equity, and inclusion (DEI) with regard to cancer immunotherapy and understudied populations
Basic Tumor Immunology
(620)
Cancer Immunotherapy in Understudied Populations
(5)
Case Reports
(192)
Clinical Trials Monitor
(17)
Clinical/Translational Cancer Immunotherapy
(1073)
Commentary/Editorials
(190)
Computational I-O
(6)
COVID-19 and Cancer Immunotherapy
(10)
Emerging Immunotherapeutic Agents
(5)
Guidelines and Consensus Statements
(61)
Guidelines and Consensus Statements
(52)
Imaging and Immunotherapy
(9)
Immune Cell Therapies and Immune Cell Engineering
(302)
Immune Checkpoints - Beyond PD-1
(8)
Immune Checkpoints Beyond PD-1 Series
(8)
Immune Monitoring Technology Primers
(12)
Immunotherapy Biomarkers
(510)
Liquid Biopsies
(8)
Microbial-Based Cancer Immunotherapy
(4)
Oncolytic and Local Immunotherapy
(172)
Reviews
(262)
SITC 40th Anniversary: I-O Progress and Potential
(7)
The Next Wave of Immuno-oncology: A Roadmap from the Society for Immunotherapy of Cancer (SITC)
(1)
Open access
(6905)
Press releases
(6)
